GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

← catalyst calendar

NCT05818150

Sponsored by Merit Medical Systems, Inc. (industry) · MMSI — their whole pipeline →.

Phase

Not applicable

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

264estimated

Sites

Countries

Australia, Brazil, Canada +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-01-16

actual

When the study began enrolling

Primary completion

Apr 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2027

estimated

The whole study's end, after follow-up

First posted

2023-04-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-10-24

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Knee Osteoarthritis

Interventions

Device: Embosphere Microspheres — also filed as Genicular artery embolization
Drug: Corticosteroid injection — also filed as Triamcinolone or methylprednisolone

Primary outcomes

what the primary-completion date above is the date OF

Primary Efficacy Endpoint

measured 6 months

Primary Safety Endpoint

measured 6 months

Publications

PMID 40050421 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · MMSI's whole pipeline · Catalyst calendar · Every registered study · What changed